Aarti Drugs Ltd (AARTIDRUGS) is currently trading at 431.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aarti Drugs Limited is an integrated Indian manufacturer of APIs, pharmaceutical intermediates, specialty chemicals and formulations, operating GMP-certified plants with an in-house formulations arm (Pinnacle Life Science) focused on regulated market dossiers and contract manufacturing. Operationally the company reported consolidated Q3 FY26 revenue of INR602.9 crores (+8% YoY) with EBITDA of INR56.3 crores and a 9.3% EBITDA margin; PAT rose sharply to INR40.5 crores (+58% YoY) driven by improved volumes and mix despite short-term utilization and pricing headwinds. Key strategic developments include the Sayakha methylamine plant (capturing backward integration for antidiabetic intermediates) and a salicylic acid facility now producing >300 tons per month; management expects rapid ramp-up of Sayakha to ~50% by Mar–Apr 2026 and further to 75%+ within the following quarters. Formulations are emerging as a higher-value growth engine: Q3 formulations revenue grew 58% YoY with 67% export share, oncology dossiers and a US/EU‑approved OSD and oncology facility at Baddi position the company to monetize higher-margin regulated markets over the medium term. Management guidance highlights normalized pricing and an inflection in realizations from January, targeted 12–15% volume growth in FY27, and disciplined capex while addressing one-time ramp-up and refurbishment impacts that compressed margins in the reported quarter.

Over the past 52 weeks, Aarti Drugs Ltd has traded between a low of ₹318.60 and a high of ₹534.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aarti Drugs Ltd has a market capitalization of approximately 3,940.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aarti Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,940.58 Cr, Aarti Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aarti Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aarti Drugs Ltd is 20.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The GST Department has filed a Special Leave Petition challenging a Bombay High Court order that was favourable to Aarti Drugs and set aside an authority order.

Consolidated revenue was reported at about ₹703 crore, while consolidated PAT was about ₹50 crore for the quarter ended June 30, 2026.

Q4 FY26 consolidated revenue was INR 721.1 crore, up 6% year-on-year and 20% quarter-on-quarter.

FY26 revenue rose 7% year-on-year to ₹2,567.7 crore, EBITDA increased 3% to ₹311.6 crore, and PAT rose 16% to ₹194.9 crore.